Study limitation: The study population had relatively short diabetes duration (mean 2.5 years) and was not on background antidiabetic therapy, which may limit generalisability to typical clinical populations | ReachRx
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Study limitation reported by the research below: “The study population had relatively short diabetes duration (mean 2.5 years) and was not on background antidiabetic therapy, which may limit generalisability to typical clinical populations.”
